Possibilities today...Treatments Tomorrow

MAY 2026

Greetings friends of NorCal and welcome to the May 2026 newsletter!

This spring, we continue to focus on finding answers for people with overweight and obesity, with and without diabetes. Carefully monitored weight loss has been strongly associated with major reductions in cardiovascular disease, sleep disorders and diabetes as well as other health problems, including back pain, hip and knee pain.

But in order to reach sustainable, safe and effective weight loss for all who need them, new drugs continue to be developed and tested that act like the groundbreaking GLP-1s but use other hormone receptors that work in different parts of the brain and gastrointestinal system.

NorCal is currently focused on three exciting weight loss studies involving unique medications being developed to provide additional treatment options for

individuals with overweight conditions of various degrees and Type 2 diabetes (recruiting now) as well as for persons without diabetes (screening now), and for those with Type 1 diabetes (coming in July)! These studies may provide special opportunities for those who have not had access to GLP1s, not been able to tolerate the side effects or have not lost significant weight on them.

The current Enlighten-2 weight loss study is for persons with overweight and Type 2 Diabetes. Enlighten-2 will further study different doses of eloralintide, a new weight loss medication that works on different appetite and intestinal receptors than the current GLP1s! Earlier studies have suggested that this unique medication works very well for weight loss and improves HA1C with few side effects.

Eloralintide may expand options for patients who couldn’t tolerate, had side effects or did not achieve weight loss success on the current GLP-1/GIP's. It may eventually also be used in combination with the GLP1-GIPs to maximize efficacy and minimize side effects.

The eloralintide data is very encouraging thus far and this Stage 3 study is being carefully conducted at over 800 international sites by Eli Lilly. Some of the prior studies of this medication have suggested that more fat and less lean body mass is lost as a percentage of total weight loss compared with GLP1/GIP's, so body composition will be followed closely as well as weight and HA1C in our year long study. See below for more details.

We have also started to seek participants for a new weekly injectable weight loss study in persons without diabetes. So be sure to call us to ensure a place if you are interested in losing weight!

This summer we’ll be studying one of the first weight loss injectables developed specifically for safe weight loss in overweight persons with Type 1 Diabetes. See below for details.

Also, new this year, we are offering FREE METABOLIC SCREENING including free HA1C, finger stick blood sugar and more. Anyone can take advantage of this free screening!!! Call to schedule.

Clinical trials are the cornerstone of evidence-based medicine. They provide the rigorous proof required to demonstrate that a new therapy is effective, alleviates suffering, or saves lives. Ultimately, these trials transform clinical practice and improve outcomes for the broader population. We extend our sincere gratitude to our patients whose participation has been vital to these scientific advancements.

Best in health,

Dr. G

Linda Gaudiani MD FACE FACP

NORCAL Medical Director

NEW TYPE 2 DIABETES

WEIGHT LOSS STUDY

Enlighten 2 Phase 3 clinical trial will study eloralintide, a long-acting form of one of the body’s own natural gluco-regulatory hormones. Although distinct, eloralintide, has benefits similar to the GLP-1s.

Earlier studies suggest excellent tolerability and efficacy and eloralintide may provide an alternative or addition to current therapies with GLP1s/GIPs. This study will use various doses to find the most effective dose with the fewest, mildest side effects.

In addition to study medication, all clinical trial participants receive ongoing dietary and lifestyle coaching as well as monetary stipends to assist with costs of travel and time. Body composition studies and glucose profiles will be followed with regular medical monitoring at in person visits as well as calls and texts. We send all records, labs and progress reports to your own primary care practitioner and work with them.

You may be eligible for Enlighten 2 if you:

have been diagnosed with T2D for at least 6 months
have an HA1C under 10.0%
are currently treated with diet/lifestyle alone or oral medications for diabetes
are 18 or over.

Please call 415-461-1585 to see if you qualify or want to learn more.

SCREENING NOW - NEW WEIGHT LOSS STUDY FOR PERSONS WITHOUT DIABETES

This Study will investigate weight management with medications Macupatide and Eloralintide, alone or in combination, in adult participants with Obesity or Overweight and without Diabetes.

You may be eligible for this study if you:

are 18 to 75 years
are obese (if your body mass index is high, BMI of ≥30 kg/m2), or
are moderately overweight, ( BMI ≥27 kg/m2) with at least one weight-related comorbidity such as hypertension, high cholesterol or triglycerides, cardiovascular disease, obstructive sleep apnea, hyperuricemia/gout, PCOS, urinary incontinence, osteoarthritis, chronic lower back pain/knee pain, metabolic liver disease (MASLD) or “fatty liver” or chronic kidney disease
have an HbA1c of under 6.5% (that is you don’t have diabetes)
have not taken weight loss medications in the past 6 months
don’t have a prior diagnosis of diabetes mellitus (except for gestational diabetes).

Call now to reserve a spot in this study. 415-461-1585.

COMING THIS SUMMER - NEW WEIGHT LOSS STUDY FOR PERSONS WITH TYPE 1 DIABETES

This study is designed to assist with safe, effective weight loss for persons with Type 1 Diabetes and mild to significant overweight or obesity. The study drug is a single molecule that has both GLP-1 and GIP actions. It is a daily injectable designed to give more flexibility, greater safety and fewer side effects for the population of T1D persons who could benefit medically from successful weight loss.

You may be eligible for this study if you:

have a documented clinical diagnosis of T1D and have been on uninterrupted insulin theraphy for 1 year
have a body mass index (BMI) of greater than 23.0
have an HbA1c of 7.0% to 10.0% as confirmed by screening lab
are able and willing to wear and utilize a CGM system during the study.

Call with any questions. 415-461-1585. This is a landmark trial as currently there are no GLP-1 type medications approved for weight loss in T1D.

FREE SCREENING FOR METABOLIC RISKS AND DISEASES

Concerned about your risk of prediabetes or diabetes? FREE SCREENING can provide valuable information. “KNOWLEDGE IS POWER!!!”

In just a few minutes, we can conduct rapid on-site screening tests and create a risk profile, which we would be happy to send to your doctor upon request. No fasting necessary.

Fingerstick HA1C test
Fingerstick blood sugar test
BMI (Body Mass Index) assessment
Risk profile

Call Jesse for info or to make a convenient appointment at 415-461-1585.

Contact us at (415) 461-1585 or Info@NorCalMedicalResearch.com with any questions or feedback and please share this newsletter with anyone you think might benefit from receiving it and finding out about our work.

If you or someone you know would like to receive this newsletter IN SPANISH, please reach out to Info@NorCalMedicalResearch.com or call our office.

Thank you for being a subscriber.

Please forward and share this newsletter with friends and family.

Did you receive it from a friend? Click HERE to subscribe and find us in your inbox every month.

Read past editions of the newsletter HERE.

JOIN OUR MAILING LIST